Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) – evidence summary new medicines (ESNM 72) -

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) – evidence summary new medicines (ESNM 72)
Information type: Evidence updates
Source: National Institute for Health
Specialities: Respiratory disorders
Summary
This review discusses the best available evidence on the efficacy and safety of tiotropium/olodaterol. Data come from 2 replicate 52‑week, double-blind, RCTs comparing tiotropium/olodaterol with the individual components in 5,163 people with COPD.
UKMi comment
Spiolto Respimat is licensed as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Related links: